VALUATION HIGHLIGHTS

1. Oncology constitutes 39% of the Trefis price estimate for Pfizer's stock.
2. Primary Care constitutes 33% of the Trefis price estimate for Pfizer's stock.
3. Specialty Care constitutes 26% of the Trefis price estimate for Pfizer's stock.

WHAT HAS CHANGED?

Latest Earnings: Q1 2026

Pfizer reported Q1 2026 revenue of $14.45 billion, representing a 5% increase year-over-year, alongside an adjusted EPS of $0.75, which beat analyst expectations despite an 18% decline from the prior year. The performance was primarily driven by a 22% operational revenue growth in launched and acquired products, with strong demand for oncology treatments like Padcev and the migraine drug Nurtec offsetting steep declines in pandemic-era vaccine and antiviral sales.

Note: Pfizer's FY'25 ended on December 31, 2025. Q1 FY'26 ended on March 31, 2026.

Commercial Reorganization

Pfizer recently implemented a strategic commercial reorganization by creating a new Global Hospital and Biosimilars Division to optimize operational focus. This move transitions certain off-patent branded and generic sterile injectables from the specialty care and oncology portfolios to better manage legacy assets while core teams concentrate on high-growth clinical areas.

POTENTIAL UPSIDE & DOWNSIDE TO TREFIS PRICE

Below are key drivers of Pfizer's value that present opportunities for upside or downside to the current Trefis price estimate:

Biopharma Segment

• Oncology Revenue Growth: The successful commercialization of the expanded oncology portfolio presents a significant upside scenario. If revenue growth outpaces the current Trefis estimate, driven by new drug approvals and deeper market penetration, the price estimate could see a notable upward revision.
• Operating Margin Pressures: As high-margin legacy product sales decline, Pfizer faces margin compression. If the enterprise cost realignment program fails to offset these declines as expected in our baseline Trefis estimate, there is downside risk to the valuation.

For additional details, select a division from the interactive Trefis split for Pfizer at the top of the page.

BUSINESS SUMMARY

Pfizer is a multinational pharmaceutical and biotechnology corporation that discovers, develops, manufactures, and markets medicines and vaccines across various therapeutic areas, including cardiovascular, oncology, immunology, and rare diseases.

SOURCES OF VALUE

The oncology and specialty care divisions represent the most significant sources of long-term value for Pfizer due to their high pricing power and extensive patent protections.

Deep Oncology Pipeline

Pfizer possesses a robust portfolio of approved cancer therapies and a deep clinical pipeline. This extensive pipeline provides a competitive advantage by ensuring a continuous stream of potential blockbuster drugs to replace those losing patent exclusivity.

Global Manufacturing and Distribution Scale

The company benefits from a massive global infrastructure that allows for rapid scaling and distribution of new drugs and vaccines. This footprint acts as a significant barrier to entry and provides a structural cost advantage over smaller biotechnology peers.

KEY TRENDS

The Approaching Patent Cliff

The pharmaceutical industry is facing a wave of patent expirations later in the decade, and Pfizer is no exception. The company is strategically positioning itself to mitigate these revenue losses through aggressive internal research and development spending and targeted acquisitions to replenish its commercial portfolio.

Enterprise Cost Realignment

Following the sharp drop in pandemic-era revenues, Pfizer has initiated a multi-year cost realignment program. This strategy aims to resize the operational footprint and reduce expenses in non-core areas, thereby protecting cash flows and supporting the dividend.